A Phase 2, Open-Label Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs Retaspimycin (Primary)
- Indications Liposarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Infinity Pharmaceuticals
- 07 Jun 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 30 Oct 2009 Planned initiation date changed from 1 Dec 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 07 Sep 2009 New trial record